linjc16/ctgov huggingface dataset:
The First Jordanian PCI Registry: Events at 1 Year

Study Overview
=================
Brief Summary
-----------------
The investigators will look at the short- (in hospital) and long- term ( 1 year)outcome in consecutive patients who undergo stent implantation and angioplasty in Jordan.

Detailed Description
-----------------
Voluntary registry of consecutive patients undergoing Percutaneous coronary intervention (PCI). Patients will be treated according to the treating cardiologists' discretion. No randomization of any medication or stent. Baseline data on admission will be collected (cardiovascular risk factors, blood lipids, ect). PCI procedure details and complications will be documented during the index admission. Outcome events (death, MI, revascularization, stent thrombosis) will be evaluated at 1, 6, and 12 months by clinic visits or phone calls.

Official Title
-----------------
The First Jordanian Percutaneous Coronary Intervention (PCI) Registry

Conditions
-----------------
Percutaneous Coronary Intervention

Intervention / Treatment
-----------------
* Procedure: Procedure: PCI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consecutive PCI patients Arab nationality Exclusion Criteria: less than 18 year of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PCI patients<br>Patients undergoing PCI for elective or ACS will be enrolled. | Procedure: Procedure: PCI<br> <br> * Other names: PCI (percutaneous coronary intervention)will be performed according to cardiologists discretion, with no randomization of stent types or medications.;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular mortality | All cases of deaths from cardiovascular causes will be counted at 1 year. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Admission for urgent coronary revascularization | All events of hospital readmission for repeat coronary intervention for acute coronary syndrome from the time of discharge from hospital up to 1 year will be documented. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Outcome after PCI, Middle Eastern Patients
The Effect of Vision Therapy/Orthoptic on Motor & Sensory Status of the 3 to 7 Years Old Strabismic Patients

Study Overview
=================
Brief Summary
-----------------
Vision therapy (VTO) is a group of non-surgical treatment helping patients in 3 subjects;1)increasing the the visual acuity 2)improving the mechanical skills resulting in increasing the power of extraocular muscles,biocular vision,peripheral vision 3) increasing the perceptual skills making the brain to percept the colour and visual memory better.In this study we are going to compare the effect of vision therapy /orthoptic on motor & sensory of the 3 to 7 years old strabismic patients

Official Title
-----------------
The Effect of Vision Therapy/Orthoptic on Motor & Sensory Status of the 3 to 7

Conditions
-----------------
Strabismus

Intervention / Treatment
-----------------
* Other: vision therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 3<age<7 Congenital isotropia Exclusion Criteria: Muscular disease General ocular and systemic disease Seizure Visual Acuity < 60/20 Nystagmus Follow up less than 3 months after surgery

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Vision therapy<br> | Other: vision therapy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
the Influence of General Anesthesia on Tumor Metastasis and Recurrence

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to investigate whether general anesthesia will affect the postoperative recurrence and metastasis of malignant tumor.

Conditions
-----------------
Tumor Recurrence and Metastasis

Intervention / Treatment
-----------------
* Other: general anesthesia and local anesthesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I - III Primary liver cancer tumor is single and diameter is less than 3 centimeter There is no major vascular invasion phenomenon, no lymph nodes or extrahepatic metastases The Child - Pugh belong to type A or type B Exclusion Criteria: Had a history of liver surgery (including radiofrequency ablation) Severe disease of heart, lung, kidney, the immune system INR > 1.5 or platelet count is less than 45000 cells/mm3 History of opioid addiction Metastatic liver tumors Not sure of primary liver cancer Don't agree to participate in this experiment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| general anesthesia<br>In this group，the patient is received radiofrequency ablation under general anesthesia. | Other: general anesthesia and local anesthesia<br>* the patient received generalanesthesia and local anesthesia randomly<br>|
| local anesthesia<br>In this group，the patient is received radiofrequency ablation under local anesthesia. | Other: general anesthesia and local anesthesia<br>* the patient received generalanesthesia and local anesthesia randomly<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with tumor recurrence and metastasis | Follow-up of patients with tumor recurrence and metastasis after Radiofrequency ablation to 3 years | 3 years |
Musculoskeletal Disorders Among Egyptian Anesthesiologists

Study Overview
=================
Brief Summary
-----------------
This cross-sectional online survey questionnaire based study for Prevalence and risk factors of work related musculoskeletal disorders among Egyptian anesthesiologists.

Detailed Description
-----------------
This cross-sectional online survey questionnaire based study will be approved by medical ethical committee of Sohag faculty of medicine. Survey participants will be reassured that all data collected are for research purposes. Responses will be voluntary anonymous and have no identifying data. Egyptian anaesthesiologists will be invited through social media to participate in the survey.

Official Title
-----------------
Prevalence and Risk Factors of Work Related Musculoskeletal Disorders Among Egyptian Anesthesiologists: a Cross-sectional Study.

Conditions
-----------------
Musculoskeletal Disorders

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Egyptian anesthesiologists on clinical practice Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention|observational study|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of work related musculoskeletal disorders among Egyptian anesthesiologists |  | April to September 2022 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factors of work related musculoskeletal disorders among Egyptian anesthesiologists |  | April to September 2022 |
Transcranial Magnetic Stimulation in the Rehabilitation of Postoperative Motor Dysfunction.

Study Overview
=================
Brief Summary
-----------------
This study focused on glioma patients with postoperative motor deficits, especially for patients with supplementary motor area syndrome. The investigators want to investigate whether the recovery of motor function will be accelerated by using transcranial magnetic stimulation to stimulate primary motor area and supplementary motor area on the lesional hemisphere.

Official Title
-----------------
A Study of Transcranial Magnetic Stimulation in the Rehabilitation of Glioma Patients With Postoperative Motor Dysfunction.

Conditions
-----------------
Glioma, Postoperative Motor Deficit

Intervention / Treatment
-----------------
* Device: TMS treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient underwent awake craniotomy and motor functional identification during tumor resection; patients with postoperative motor deficit (muscle strength of limbs is weaker than preoperative status) Exclusion Criteria: patients with contraindication of transcranial magnetic stimulation; patients without data of the pre- and postoperative resting state MRI and diffusion tensor image.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: patients with postoperative motor deficits, especially for patients with SMA syndrome.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TMS treatment<br>Patients with TMS treatment | Device: TMS treatment<br>* Using TMS to stimulate (5 Hz, 90% 110% resting motor threshold) patients' primary motor area and SMA.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accelerate motor functional recovery | The ratio of motor functional recovery in patients with TMS treatment is higher than those do not receive TMS treatment and the time of motor funcitonal recovery is shorter than those do not receive. | From the day of tumor resection to 3 months after tumor resection. |
Study of Predictors of Failure of Sulprostone Treatment in Postpartum Hemorrhage

Study Overview
=================
Brief Summary
-----------------
The investigators wish to identify potential factors predicting failure of second-line drug treatment (sulproston (Nalador®)): risk factors and factors linked to a failure to take initial care for PPH. A better understanding of the aggravating factors of HPP and more particularly the factors inherent to the initial care would make it possible to think of ways to improve practices.

Official Title
-----------------
Study of Predictors of Failure of Sulprostone Treatment in Postpartum Hemorrhage

Conditions
-----------------
Postpartum Hemorrhage

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major subject (≥18 years old) Subject having given birth at HUS or CHU Poissy Saint-Germain-en Laye between 01/01/2019 and 31/12/2019 Subject having presented a postpartum haemorrhage treated with Sulprostone Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research Exclusion Criteria: Subject having expressed opposition to participating in the study Subject under guardianship or guardianship Subject under safeguard of justice

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify a potential predictors of failure of second-line drug treatment in the case of severe postpartum hemorrhage |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Maternal morbidity, Postpartum haemorrhage, Oxytocin, Sulprostone, Uterine Hemorrhage, Obstetric Labor Complications
Evaluation of Single-dose Pharmacokinetics of Intravenous Daptomycin in Patients With Thermal Injury

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine single dose pharmacokinetics of daptomycin consecutively in 10 patients on three different time points after severe burn injury.

Official Title
-----------------
Evaluation of Single-dose Pharmacokinetics of Intravenous Daptomycin in Patients With Thermal Injury

Conditions
-----------------
Burn Injury

Intervention / Treatment
-----------------
* Drug: Daptomycin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female of 18 years or older Second and/or third degree thermal injury Total body surface area burned ≥ 15% Hospitalisation in the ICU for burn injured patients of the University Hospital Zürich Probability of ICU stay of >14 days Written informed consent by the patient or in patients unable to be informed or to sign according to section 4.4 of the study protocol Exclusion Criteria: Evidence of renal failure (Creatinine clearance <30ml/min) or continuous renal replacement therapy such as continuous hemofiltration History of muscle disease or skeletal muscle disorder Creatine-phosphokinase (CPK) ≥ 5 times the upper limit of normal (ULN) History of hypersensitivity to the drug Pregnancy Severe coagulation disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Daptomycin<br> | Drug: Daptomycin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetic parameters of daptomycin |  | up to 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of daptomycin plasma concentrations with tissue concentration |  | up to 30 days | 
| degree of variability of daptomycin pk parameters in dependency of body surface area burned |  | up to 30 days |
Antibiotics in Chronic Obstructive Pulmonary Disease (COPD)

Study Overview
=================
Brief Summary
-----------------
It is not clear whether antibiotic therapy is needed in patients with mild to moderate exacerbation of chronic obstructive lung disease. The aim of the study is to compare the effect of 1 day of treatment with 6 days of treatment in patients who are admitted to hospital and being clinical stable (as judged by their physician) 24 hours after hospitalization

Official Title
-----------------
Antibiotic Treatment of Patients Admitted to Hospital With Acute Exacerbation of COPD. Effect of 1 Day of Antibiotic Therapy Compared to 6 Days of Therapy in Patients Who Are Stable After 24 Hours

Conditions
-----------------
Pulmonary Disease, Chronic Obstructive

Intervention / Treatment
-----------------
* Drug: Doxycycline
* Drug: Placebo (matching)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age above 50 years History of smoking History of COPD Antibiotics for 24 hours At least 2 of the following: dyspnoea, coughing with sputum, and sputum with purulence Informed consent Exclusion Criteria: Pneumonia Antibiotics for more than 36 hours Antibiotics for other infection Prednisolone, more than 0.5 mg/kg body weight/24 hours for more than 3 days Malignancy Other pulmonary disease Immune deficiency Not able to tolerate doxycycline Severe heart, liver or kidney disease Epilepsia Not stable 24 hours after hospital admission Need for assisted ventilation

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Doxycycline<br>Doxycycline 200 mg QD in 5 days | Drug: Doxycycline<br>* 200 mg QD in 5 days<br>|
| Placebo Comparator: Placebo<br>Matching placebo QD i 5 days | Drug: Placebo (matching)<br>* Placebo QD i 5 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 6 minutes walking distance |  | Day 14 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to next episode of acute exacerbation |  | Days 14, 30, 90 and 180 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic obstructive pulmonary disease, Infection, Antibiotics
Plasma EBV DNA Monitoring in Post-treatment NPC Patients

Study Overview
=================
Brief Summary
-----------------
Continuous regular monitoring of plasma EBV DNA in nasopharyngeal carcinoma (NPC) after treatment have rarely been investigated. The investigators try to analyze the long-term observational results (role in early relapse detection and impact on survival) in NPC patients after curative treatment.

Detailed Description
-----------------
The investigators enrolled 441 NPC patients who had finished finished curative radiotherapy with/without chemotherapy and no recurrence/metastasis before entry this study from five hospitals in Taiwan. Blood samples were collected on the day of enrollment and monitored once every 2-3 months for plasma EBV DNA measurement. After long-term observation, we analyze the impact of continuous plasma EBV DNA monitoring on the early dection of tumor relapse and do risk grouping for survival analyses according to the blood test results.

Official Title
-----------------
Long-term Results of Plasma Epstein-Barr Virus DNA Monitoring In Nasopharyngeal Carcinoma After Curative Treatment

Conditions
-----------------
Nasopharyngeal Carcinoma, NPC, EBV, Radiotherapy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria histologically-proven nasopharyngeal carcinoma without distant metastasis (M0) at initial presentation finished curative radiotherapy (with/without chemotherapy) within 3 years Exclusion criteria no occurrence of documented recurrence/metastasis before entry

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with NPC after treatment<br>All patients with NPC without distant metastases who receiving adequate RT dose | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time interval from the date of abnormal blood test to the date of clinically documented tumor relapse | From the end of treatment to any time when abnormal blood test is fund | Five years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival (OS) | Overall survival was calculated from the day of enrollment until death or the last follow-up visit | Five years | 
| Event-free survival (EFS) | Event-free survival was calculated from the day of enrollment until the date of first occurrence of tumor relapse (local, regional, or distant failures) or the last follow-up visit | Five years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nasopharyngeal Carcinoma, NPC, EBV, Radiotherapy, Plasma Epstein-Barr virus DNA
Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)

Study Overview
=================
Brief Summary
-----------------
This is an open-label, extension, Phase III study to evaluate the long-term safety, efficacy and PK of MRA in patients with pJIA who participated in Study MRA318JP.

Official Title
-----------------
An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety, Efficacy and PK of MRA in Patients With pJIA Who Participated in Study MRA318JP

Conditions
-----------------
Polyarticular Juvenile Idiopathic Arthritis

Intervention / Treatment
-----------------
* Drug: MRA(Tocilizumab)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Of the patients who received three infusions with MRA in the previous study and for whom a last observation was conducted the patients who did not have problems with safety in the previous study Exclusion criteria Patients who were not enrolled by 3 months after completion of the previous study Patients who received any of the following since completion of the previous study until initiation of treatment in the present study DMARDs or immunosuppressants Intravenous and intramuscular injection of corticosteroids Plasma exchange therapy Other drugs and therapies that may affect evaluation of drug efficacy

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: MRA(Tocilizumab)<br>* 8mg/kg/4weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy:Percentage of patients showing 30% improvement in the JIA core set every 3M, LOBS |  | every 3 months | 
| Safety:Incidence and severity of adverse events and adverse drug reactions |  | whole period | 
| Pharmacokinetics:The time course of the trough values for the serum MRA concentration |  | whole period | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy:The time course of the percentage of patients showing 30%, 50%, and 70% improvement in the JIA core set, each variable of the JIA core set, CRP, pain every 3M, LOBS |  | every 3 months |